熱門資訊> 正文
NeoGenomics在Natera专利纠纷中获胜后集会
2025-08-29 20:45
- NeoGenomics (NASDAQ:NEO) shares climbed ~20% in the premarket on Friday after the company announced a major victory in a legal battle over a patent dispute with its rival cancer test developer Natera (NASDAQ:NTRA).
- In a statement on Friday, the company stated that a federal judge in North Carolina granted its motion for summary judgment after determining that Natera’s (NASDAQ:NTRA) asserted patents were invalid due to claims of trivial subject matter.
- The District Court for the Middle District of North Carolina has stated it will dismiss the NTRA’s claims with prejudice, meaning that another case over the same claims cannot be brought back to the court.
- The judgment allows NeoGenomics (NASDAQ:NEO) to commercialize its cancer test RaDaR ST assay, formerly known as RaDaR 1.1, without any constraints in the U.S.
More on NeoGenomics, Natera
- Natera, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript
- NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript
- Natera raises revenue guidance to $2.1B and targets margin expansion through AI-driven efficiencies
- Natera GAAP EPS of -$0.74 misses by $0.13, revenue of $546.6M beats by $69.76M
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
